SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Wayfinder

Wayfinder's PROMPT.X is trending with community members citing potential breakouts and significant gains, with some suggesting accumulation during dips. Bullish sentiment is fueled by mentions of strong support levels and potential short squeezes, while others point to increased volume and a possible reversal after a period of decline. The coin is being compared to other altcoins, with some speculating on potential future price targets.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending due to community speculation about a potential acquisition by Nvidia ($NVDA) and excitement surrounding its role in powering AI data centers. Traders are also closely monitoring insider trading activity and the impact of the new CEO on the company's strategic direction within the AI sector. Discussions also include potential breakout opportunities.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders tout receiving $SOL.X rewards directly into their wallets just for holding, with the community emphasizing the ease and passive income potential of the token. Discussions highlight the strength and resilience of the community, especially after recent changes and new developments, with a bare knuckle fight sponsorship with Kimbo Slice Jr. also generating buzz.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Pump.fun

$PUMP.X is trending as community members discuss its potential for significant gains, with some highlighting its strong chart and recent updates. Conversations also mention the coin's resilience and potential breakout, with many expressing excitement about its future prospects within the Solana ecosystem. Some users suggest this could be a long-term play, while others are actively trading the volatility.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as discussions emerge around its potential role in decentralized finance and real-world asset tokenization following a U.S. Department of Commerce announcement. The community is focused on Pyth's utility, comparing it to other oracles like Chainlink, and anticipating further price appreciation. Bullish sentiment is fueled by the expectation that the network will disrupt the traditional finance sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.

Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 3rd 

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (Amicus) on behalf of the companys shareholders. Click here for additional information...

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts

Latest Ratings for FOLD
 DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jan 2022SVB LeerinkUpgradesMarket PerformOutperform Jan 2022Cantor FitzgeraldMaintainsOverweight
 View More...

Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.03	--	--	N/A
Q2 '25	-$0.12	-$0.08	32.02%	BEAT
Q1 '25	-$0.05	-$0.07	-29.05%	MISSED
Q4 '24	$0.01	$0.05	544.75%	BEAT
Q3 '24	$0.00	-$0.02	-1792.05%	MISSED

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest FOLD News

FOLD Amicus Therapeutics Inc